These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33823566)

  • 21. PD-L1 assessment in urothelial carcinoma: a practical approach.
    Eckstein M; Cimadamore A; Hartmann A; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R; Gevaert T
    Ann Transl Med; 2019 Nov; 7(22):690. PubMed ID: 31930091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review.
    Prince EA; Sanzari JK; Pandya D; Huron D; Edwards R
    JCO Precis Oncol; 2021 Jun; 5():953-973. PubMed ID: 34136742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma.
    Lee KS; Choe G; Yun S; Lee K; Moon S; Lee S; Hong SK; Byun SS; Lee SE
    Histopathology; 2020 Jul; 77(1):67-78. PubMed ID: 31872892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
    Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
    Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
    Munari E; Rossi G; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Netto GJ; Hoque MO; Brunelli M; Martignoni G; Haffner MC; Moretta F; Pegoraro MC; Cavazza A; Samogin G; Furlan V; Mariotti FR; Vacca P; Moretta L; Bogina G
    Am J Surg Pathol; 2018 Oct; 42(10):1384-1389. PubMed ID: 29901568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
    Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
    J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays.
    Evans H; O'Sullivan B; Hughes F; Charles K; Robertson L; Taniere P; Diaz-Cano S
    Pathol Oncol Res; 2022; 28():1610260. PubMed ID: 35478498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC.
    Williams GH; Nicholson AG; Snead DRJ; Thunnissen E; Lantuejoul S; Cane P; Kerr KM; Loddo M; Scott MLJ; Scorer PW; Barker C
    J Thorac Oncol; 2020 Apr; 15(4):550-555. PubMed ID: 31778799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study.
    Kim H; Kwon HJ; Park SY; Park E; Chung JH
    Oncotarget; 2017 Nov; 8(58):98524-98532. PubMed ID: 29228707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
    Watanabe T; Okuda K; Murase T; Moriyama S; Haneda H; Kawano O; Yokota K; Sakane T; Oda R; Inagaki H; Nakanishi R
    Oncotarget; 2018 Apr; 9(29):20769-20780. PubMed ID: 29755688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer.
    Pang C; Yin L; Zhou X; Lei C; Tong R; Huang M; Gong Y; Ding Z; Xue J; Zhu J; Wang Y; Ren L; Zhou L; Wang J; Peng F; Zhou Q; Lu Y
    J Thorac Dis; 2018 Feb; 10(2):816-824. PubMed ID: 29607153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Consistency of PD-L1 immunohistochemical detection platforms in biopsy samples with advanced lung adenocarcinoma: a multicenter study].
    Yuan P; Guo CY; Li Y; Jiang LL; Liu YP; Liu XY; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):840-844. PubMed ID: 30423607
    [No Abstract]   [Full Text] [Related]  

  • 34. PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
    Brown LC; Zhu J; Labriola MK; Wu Y; Cheris S; Liu X; Perkinson K; Su Z; McCall S; Huang J; Foo WC; Gupta RT; Armstrong AJ; George DJ; Harrison MR; Zhang T
    Clin Genitourin Cancer; 2020 Dec; 18(6):509-513. PubMed ID: 32482566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
    Zajac M; Boothman AM; Ben Y; Gupta A; Jin X; Mistry A; Sabalos C; Nielsen A; Manriquez G; Barker C; Antal J; Wang P; Patil P; Schechter N; Rebelatto MC; Walker J
    Arch Pathol Lab Med; 2019 Jun; 143(6):722-731. PubMed ID: 30457897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.
    Schats KA; Van Vré EA; Boeckx C; De Bie M; Schrijvers DM; Neyns B; De Meester I; Kockx MM
    Arch Pathol Lab Med; 2018 Aug; 142(8):982-991. PubMed ID: 29607663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.
    Munari E; Zamboni G; Lunardi G; Marconi M; Brunelli M; Martignoni G; Netto GJ; Quatrini L; Vacca P; Moretta L; Bogina G
    Hum Pathol; 2019 Aug; 90():54-59. PubMed ID: 31121194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
    Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype.
    Kim B; Lee C; Kim YA; Moon KC
    Front Oncol; 2020; 10():527385. PubMed ID: 33365265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.